RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q3 FY20 results · Oct–Dec 2019
RPG Life Sciences reported revenue from operations of ₹94.37 crore (up 3.7% from Q3 FY19) and net profit of ₹7.91 crore (up 49.8% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a standalone basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 94.37 | 90.97 | +3.7% | 98.49 | −4.2% |
| Other income | 0.04 | 0.02 | +100.0% | 0.15 | −73.3% |
| Total income | 94.41 | 90.99 | +3.8% | 98.64 | −4.3% |
| Profit before tax | 10.41 | 7.25 | +43.6% | 12.04 | −13.5% |
| Net profit for the period | 7.91 | 5.28 | +49.8% | 9.77 | −19.0% |
| EPS, basic (₹) | 4.78 | 3.19 | +49.8% | 5.91 | −19.1% |
| Net margin (%) | 8.4 | 5.8 | 9.9 |
Standalone
- Filed with BSE
- 01 Feb 2020, 15:26 IST
- Board meeting
- 31 Jan 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE